Showing 5391-5400 of 20465 results for "".
- Genetic Score in ZMIZ1/TGF‑β/STAT Pathway Forecasts Biologic Drug Persistence in Psoriasishttps://reachmd.com/news/genetic-score-in-zmiz1tgfstat-pathway-forecasts-biologic-drug-persistence-in-psoriasis/2483888/In a newly published study in Advances in Therapy, investigators report that a pathway‑based genetic score may predict how long patients with moderate
- Experimental Nanobody Shows Promise for Psoriatic Arthritis in Phase 2 Trialhttps://reachmd.com/news/experimental-nanobody-shows-promise-for-psoriatic-arthritis-in-phase-2-trial/2483875/A novel nanobody therapy targeting dual inflammatory pathways has shown encouraging results in treating psoriatic arthritis (PsA), a complex and disabling autoimmune disease. The investigational agent
- Measles Resurgence Oct 2025: Linking Alberta’s Surge and U.S. Clusters to Vaccination Gaps and Policy Responseshttps://reachmd.com/news/measles-resurgence-oct-2025-linking-albertas-surge-and-us-clusters-to-vaccination-gaps-and-policy-responses/2483879/The near-1,914-case measles surge in Alberta since March 2025, coupled with emerging U.S. clusters, represents a preventable re-establishment risk for elimination-era regions and demands immediate clinical and public-health attention. Rapid operational adjustments now can blunt cross-border
- Rare Case of Urachal Neuroendocrine Carcinoma Reveals Potential for Targeted Therapyhttps://reachmd.com/news/rare-case-of-urachal-neuroendocrine-carcinoma-reveals-potential-for-targeted-therapy/2483886/In a newly published case report, Japanese researchers describe one of the few documented instances of neuroendocrine carcinoma (NEC) arising from the urachus, providing detailed pathological
- Dual-Targeting Nanobody Sonelokimab Shows Promise in Psoriatic Arthritis Phase 2 Trialhttps://reachmd.com/news/dual-targeting-nanobody-sonelokimab-shows-promise-in-psoriatic-arthritis-phase-2-trial/2483881/A novel nanobody therapy targeting dual inflammatory pathways has shown encouraging results in treating psoriatic arthritis (PsA), a complex and disabling autoimmune disease. The investigational agent,
- Analysis: Ceramide Skincare from Birth May Mitigate Pediatric ADhttps://reachmd.com/news/analysis-ceramide-skincare-from-birth-may-mitigate-pediatric-ad/2483872/A new consensus paper offers clinical recommendations to address the complex interplay of skin barrier dysfunction and SAIGE (Staphylococcus aureus colonization, immunologic, genetic, and environmental) factors in pediatric atopic dermatitis (AD).
- Mitochondrial Gene Signatures Linked to Heart Damage in Childhood Cancer Survivorshttps://reachmd.com/news/mitochondrial-gene-signatures-linked-to-heart-damage-in-childhood-cancer-survivors/2483866/A new study published in Cardio-Oncology offers compelling evidence that anthracycline-induced cardiomyopathy—a serious and often delayed complication of chemotherapy—may be driven by widesp
- New T Cell Subset Linked to Bone Loss in Rheumatoid Arthritis, Offering Novel Therapeutic Targethttps://reachmd.com/news/new-t-cell-subset-linked-to-bone-loss-in-rheumatoid-arthritis-offering-novel-therapeutic-target/2483864/A newly identified subset of regulatory T cells, known as iTr35 cells, may play a critical role in protecting against bone loss in patients with rheumatoid arthritis (RA), according to a p
- Registration Open for 2026 Octane Aesthetics Tech Forumhttps://reachmd.com/news/registration-open-for-2026-octane-aesthetics-tech-forum/2483870/Aesthetic executives, leading physicians, and entrepreneurs will dive into the latest trends and technology in aesthetic medicine at the 2026 Octane Aesthetics Tech Forum. The 2-day forum will be held January 8-9 at the Pendry in Newport Beach, California. The agenda includes sessions on
- Dr. Jennifer Soung: Ask Patient’s Permission Before Talking GLP-1shttps://reachmd.com/news/dr-jennifer-soung-ask-patients-permission-before-talking-glp-1s/2483863/GLP-1 treatments have become commonplace in dermatology practices, with both aesthetic and medical dermatology implications heavily involved. Talking to patients about the latter issue, however, can prove challenging. Despite the mounting literature indicating that GLP-1 agonists can help allevia